SCHEMBL14039474

SCHEMBL14039474

CCCc1cccc(N(C)C(=O)c2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.48
TSHR P16473 1/20 0.47
HTT P42858 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
MDM2 Q00987 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
KAT6A Q92794 1/20 0.46
HSD17B2 P37059 4/20 0.46
HSD17B1 P14061 3/20 0.46
EGFR P00533 1/20 0.46
ERBB2 P04626 1/20 0.46
TRPV1 Q8NER1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1696343 0.91 L3MBTL1 (0.55) KMT2AL3MBTL1KDM4EMEN1TSHR
SCHEMBL15676780 0.88 SIGMAR1 (0.56) KMT2AL3MBTL1KDM4EMEN1TSHR
SCHEMBL18780868 0.85 KMT2A (0.55) KMT2AL3MBTL1KDM4EMEN1TSHR
SCHEMBL13951769 0.85 HSD17B2 (0.56) KMT2AL3MBTL1KDM4ETSHRHTT
SCHEMBL1690907 0.84 KMT2A (0.51) KMT2AL3MBTL1KDM4EMEN1TSHR
SCHEMBL27326764 0.84 KMT2A (0.54) KMT2AL3MBTL1KDM4EMEN1TSHR
SCHEMBL13181080 0.83 ESR1 (0.55) KMT2AKDM4EMEN1TSHRHTT
SCHEMBL1696607 0.82 PLAU (0.43) KMT2AL3MBTL1MEN1HTTNPC1
SCHEMBL10273801 0.82 ITGB1 (0.44) HTTNPC1RAB9AALDH1A1SIGMAR1
SCHEMBL9001629 0.82 KMT2A (0.62) KMT2AL3MBTL1KDM4ETSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed